The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
BPR0L075, a Novel Synthetic Indole Compound with Antimitotic Activity in Human Cancer Cells, Exerts Effective Antitumoral Activityin Vivo
Abstract
BPR0L075 is a novel synthetic compound discovered through research to identify new microtubule inhibitors. BPR0L075 inhibits tubulin polymerization through binding to the colchicine-binding site of tubulin. Cytotoxic activity of BPR0L075 in a variety of human tumor cell lines has been ascertained, with IC50 values in single-digit nanomolar ranges. As determined by flow cytometry, human cervical carcinoma KB cells are arrested in G2-M phases in a time-dependent manner before cell death occurs. Terminal deoxynucleotidyl transferase-mediated nick end labeling assay indicates that cell death proceeds through an apoptotic pathway. Additional studies indicate that the effect of BPR0L075 on cell cycle arrest is associated with an increase in cyclin B1 levels and a mobility shift of Cdc2 and Cdc25C. The changes in Cdc2 and Cdc25C coincide with the appearance of phosphoepitopes recognized by a marker of mitosis, MPM-2. Furthermore, phosphorylated forms of Bcl-2, perturbed mitochondrial membrane potential, and activation of the caspase-3 cascade may be involved in BPR0L075-induced apoptosis. Notably, several KB-derived multidrug-resistant cell lines overexpressing P-gp170/MDR and MRP are resistant to vincristine, paclitaxel, and colchicine but not to BPR0L075. Moreover, BPR0L075 shows potent activity against the growth of xenograft tumors of the gastric carcinoma MKN-45, human cervical carcinoma KB, and KB-derived P-gp170/MDR-overexpressing KB-VIN10 cells at i.v. doses of 50 mg/kg in nude mice. These findings indicate BPR0L075 is a promising anticancer compound with antimitotic activity that has potential for management of various malignancies, particularly for patients with drug resistance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Yung-Chi, C., & Prusoff, W. H. (1973) · Biochemical Pharmacology · doi:10.1016/0006-2952(73)90196-2 · Cited by 12,922
Cited by
An overview of tubulin inhibitors that interact with the colchicine binding site
Lu, Y., Chen, J., Xiao, M., Li, W., & Miller, D. D. (2012) · Pharmaceutical Research · doi:10.1007/s11095-012-0828-z · Cited by 709
Indole, a core nucleus for potent inhibitors of tubulin polymerization
Brancale, A., & Silvestri, R. (2007) · Medicinal Research Reviews · doi:10.1002/med.20080 · Cited by 344
Huang, W.-L., Yeh, H.-H., Lin, C.-C., Lai, W.-W., Chang, J.-Y., Chang, W.-T., & Su, W.-C. (2010) · Molecular Cancer · doi:10.1186/1476-4598-9-309 · Cited by 86
Self-citation
Metadata
- Authors
- Kuo, C.-C., Hsieh, H.-P., Pan, W.-Y., Chen, C.-P., Liou, J.-P., Lee, S.-J., Chang, Y.-L., Chen, L.-T., Chen, C.-T., & Chang, J.-Y.
- Venue
- Cancer Research
- Published
- 2004-07-01
- Volume
- 64
- Issue
- 13
- Pages
- 4621-4628
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W2098816850
- Cited by
- 201
- References
- 1
- FWCI
- 3.44
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: BPR0L075, a Novel Synthetic Indole Compound with Antimitotic Activity in Human Cancer Cells, Exerts Effective Antitumoral Activityin Vivo. https://app.cochat.ai/papers/10.1158/0008-5472.can-03-3474
- The paper
- Kuo, C.-C., Hsieh, H.-P., Pan, W.-Y., Chen, C.-P., Liou, J.-P., Lee, S.-J., Chang, Y.-L., Chen, L.-T., Chen, C.-T., & Chang, J.-Y. (2004). BPR0L075, a Novel Synthetic Indole Compound with Antimitotic Activity in Human Cancer Cells, Exerts Effective Antitumoral Activityin Vivo. Cancer Research. https://doi.org/10.1158/0008-5472.can-03-3474
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.